Bioxytran Published A Surrogate Marker for ARDS and Stroke Patients
April 03, 2020 07:00 ET
|
Bioxytran Inc.
Journal article published specifies the use of the MDX Viewer as an early warning sign of negative oxygen balance for use in Acute Respiratory Deficiency Syndrome (ARDS). BOSTON, MASSACHUSETTS,...
Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
March 31, 2020 07:00 ET
|
Bioxytran Inc.
Company releases new COVID-19 slide deck on website. BOSTON, MASSACHUSETTS, March 31, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a...
Bioxytran to Internally Develop Novel Carbohydrate Galectin Inhibitor to Eliminate COVID-19 in Patients
March 30, 2020 10:40 ET
|
Bioxytran Inc.
Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported. BOSTON, MASSACHUSETTS, March 30,...
Bioxytran Licenses Novel Viral Inhibitor for COVID-19 Patients
March 24, 2020 08:48 ET
|
Bioxytran Inc.
The viral inhibitor is a polysaccharide designed to block galectins BOSTON, MASSACHUSETTS, March 24, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT), a developmental stage biotechnology...
Bioxytran Guest Speaker on Perfusionists Continuing Education Program Discussing Acute Respiratory Distress Syndrome and Ways to Combat COVID-19
March 12, 2020 07:00 ET
|
Bioxytran Inc.
Live Youtube Broadcast with Expert Panelists on March 26, 2020 in MediWeb Studios BOSTON, MASSACHUSETTS, March 12, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), a developmental stage...
Bioxytran Positioned to Detect and Treat Stroke and Neuropathologies
February 28, 2020 10:25 ET
|
Bioxytran Inc.
Journal Article correlates different neurological pathologies with Brain Metabolic Score and examines a neurological case study BOSTON, MASSACHUSETTS, Feb. 28, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN,...
Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
February 05, 2020 07:00 ET
|
Bioxytran Inc.
BXT-25 has the potential to treat late stage acute respiratory distress syndrome (ARDS) which is the leading cause of death in coronavirus patients. BOSTON, MASSACHUSETTS, Feb. 05, 2020 (GLOBE...
Bioxytran’s MDX Viewer in conjunction with BXT-25 Will Validate Brain Metabolic Score as a Functional Endpoint in Ischemic Stroke
December 05, 2019 15:45 ET
|
Bioxytran Inc.
Journal Article Evaluates Viability of Neuroprotectants as a functional Endpoint in Ischemic Stroke and Other Diseases BOSTON, MASSACHUSETTS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
Bioxytran Unveiling Concept of a new Vital Sign at Targeting Mitochondria World Congress
October 28, 2019 14:02 ET
|
Bioxytran Inc.
MDX Viewer provides essential data in critical care patientsBOSTON, MASSACHUSETTS, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company focused...
Latest Nobel Prize Validates Bioxytran at the Forefront of Scientific Discovery
October 16, 2019 07:00 ET
|
Bioxytran Inc.
Platform technology destined to measure and treat hypoxia BOSTON, MASSACHUSETTS, Oct. 16, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), is a developmental stage biotechnology...